212061-27-3

Basic information

• Product Name: Uridine, 2'-O-[2-[(dimethylamino)oxy]ethyl]-5'-O-[(1,1-dimethylethyl)diphenylsilyl]- 5-methyl-
• CAS NO: 212061-27-3
• Molecular Formula: C30H41N3O7Si
• Molecular Weight: 583.757
• Mol File: 212061-27-3.mol
• Article Data: 238

Chemical Properties

• CAS DataBase Reference: Uridine, 2'-O-[2-[(dimethylamino)oxy]ethyl]-5'-O-[(1,1-dimethylethyl)diphenylsilyl]- 5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Uridine, 2'-O-[2-[(dimethylamino)oxy]ethyl]-5'-O-[(1,1-dimethylethyl)diphenylsilyl]- 5-methyl-(212061-27-3)
• EPA Substance Registry System: Uridine, 2'-O-[2-[(dimethylamino)oxy]ethyl]-5'-O-[(1,1-dimethylethyl)diphenylsilyl]- 5-methyl-(212061-27-3)

Safety Data

• Hazardous Substances Data: 212061-27-3(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 212061-26-2 2'-O-[(2-formadoxyiminooxy)ethyl]-5'-O-tert-butyldiphenylsilyl-5-methyluridine 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 25895-60-7 sodium cyanoborohydride 
• 244277-62-1 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine 
• 258501-33-6 1-{5-(tert-butyl-diphenyl-silanyloxymethyl)-4-hydroxy-3-[2-(N-methyl-aminooxy)-ethoxy]-tetrahydro-furan-2-yl}-5-methyl-1H-pyrimidine-2,4-dione 
• 212061-25-1 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)oxy]ethyl]-5-methyluridine 
• 212061-24-0 5'-O-(tert-butyldiphenylsilyl)-2'-O-(2-hydroxyethyl)-5-methyluridine 
• 171763-19-2 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 

Downstream Products

• 315701-92-9 N⁴-benzoyl-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-05-8 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-06-9 N⁴-benzoyl-3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 1463-10-1 5-Methyluridine 
• 212061-29-5 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine 
• 400821-04-7 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methyluridine 

Relevant articles and documents

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.

Antisense modulation of inducible nitric oxide synthase expression

Antisense compounds, compositions and methods are provided for modulating the expression of inducible nitric oxide synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inducible nitric oxide synthase. Methods of using these compounds for modulation of inducible nitric oxide synthase expression and for treatment of diseases associated with expression of inducible nitric oxide synthase are provided.